Screener
Axsome Therapeutics AXSM Operating Income
Operating Income at other companies
Other financials
Where this comes from
Reported directly by Axsome Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: Axsome Therapeutics’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 5:04 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-204274
| Line item | Three months ended March 31, 2026 | Three months ended March 31, 2025 |
|---|---|---|
| Loss in fair value of contingent consideration | 590 | 1,512 |
| Intangible asset amortization | 1,572 | 1,572 |
| Total operating expenses | 254,560 | 178,445 |
| Loss from operations | (63,357) | (56,982) |
| Interest expense, net | (1,185) | (2,431) |
| Loss before income taxes | (64,542) | (59,413) |
| Income tax expense | — | — |
| Net loss | $(64,542) | $(59,413) |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Axsome Therapeutics's operating income?
- Axsome Therapeutics (AXSM) reported operating income of -$63.36M in Q1 2026.
- How has Axsome Therapeutics's operating income changed year-over-year?
- Axsome Therapeutics's operating income decreased by 11.2% year-over-year, from -$56.98M to -$63.36M.
- What is the long-term trend for Axsome Therapeutics's operating income?
- Over 4 years (2021 to 2025), Axsome Therapeutics's operating income has grown at a 7.5% compound annual growth rate (CAGR), from -$124.71M to -$166.76M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.
Ask your AI about Axsome Therapeutics's operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude